Renovar

Renovar is a biotechnology company dedicated to improving the management of kidney health through non-invasive diagnostic and prognostic solutions. The company specializes in developing urine-based biomarker assays that monitor the health of kidney transplants, allowing for the early detection of subclinical rejection and acute injury. Their flagship product, RenaSure, utilizes the CXCL9 protein biomarker to provide a reliable alternative to invasive and costly needle biopsies. By enabling more frequent and safer monitoring, Renovar's technology aims to optimize immunosuppressive therapy and extend the long-term survival of transplanted organs. The company's research also extends to monitoring chronic kidney disease progression and acute kidney injury.